{"title":"摘要OT-28-06:在HER2过表达实体瘤患者中,腺病毒转导的自体巨噬细胞被改造成含有抗HER2嵌合抗原受体,这是人类首次进行一期研究","authors":"N. Grover, D. Barton, A. Ronczka, J. Bauml","doi":"10.1158/1538-7445.sabcs20-ot-28-06","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":342683,"journal":{"name":"Ongoing Clinical Trials Abstracts","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract OT-28-06: A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors\",\"authors\":\"N. Grover, D. Barton, A. Ronczka, J. Bauml\",\"doi\":\"10.1158/1538-7445.sabcs20-ot-28-06\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":342683,\"journal\":{\"name\":\"Ongoing Clinical Trials Abstracts\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ongoing Clinical Trials Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.sabcs20-ot-28-06\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ongoing Clinical Trials Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.sabcs20-ot-28-06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract OT-28-06: A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors